{"entity":{"id":"nct07561775","kind":"trial","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","aka":[],"tldr":"A phase 2 trial of adebrelimab and S-1 in gallbladder cancer and other biliary tract cancers, run by Xingjun Guo, not yet recruiting.","summary":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma is a phase 2 interventional study registered as NCT07561775 by Xingjun Guo, with a registry enrolment figure of 40 participants, started 2026-04-21 and due to reach its primary completion in 2028-01-01. Interventions recorded: Adebrelimab, S-1. Conditions listed: Cholangiocarcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07561775","url":"https://clinicaltrials.gov/study/NCT07561775"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["adebrelimab","tegafur-gimeracil-oteracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07561775","phase":"2","setting":"A Single-Arm, Exploratory Clinical Study of Adebrelimab Combined With S-1 in Patients With Resected Cholangiocarcinoma","sponsor":"Xingjun Guo","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07561775/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}